Skip to content

US · DYN · BIOTECHNOLOGY

Dyne Therapeutics, Inc. (DYN) intrinsic value and stock valuation

$15.50as of 2026-11-21 · Mkt cap 4.89B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dyne Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DYN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DYN’s statements →

Dyne Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 dyne-tx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-446.21M
20112025
Free cash flow
-$-405.13M
20112025
Total equity
$972.1M+23.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-468.18M-$-343.89M-$-242.16M-$-170.96M-$-150.03M
Net income-$-446.21M-$-317.42M-$-235.94M-$-168.1M-$-149.29M
EPSd-$-3.47M-$-3.37M-$-3.95M-$-3.23M-$-2.93M
Operating cash flow-$-403.21M-$-292.37M-$-188.16M-$-153.65M-$-119.56M
Capital expenditure-$-1.92M-$-2.38M-$-730K-$-3.07M-$-3.62M
Free cash flow-$-405.13M-$-294.75M-$-188.89M-$-156.71M-$-123.18M
Total assets$1.19B$691.2M$165.1M$306.3M$425.7M
Total debt$20.3M$24M$27.4M$30.5M$32.6M
Net debt-$-873.09M-$-411.46M-$-94.21M-$-141.66M-$-168.19M
Total equity$972.1M$629.8M$91.3M$252.4M$368.2M
Cash and short-term investments$1.11B$642.3M$123.1M$256M$376.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$2.05M$2.24M$2.46M$0.00$0.00
Gross profit-$-2.05M-$-2.24M-$-2.46M$0.00$0.00
Research and development expenses$398.3M$281.4M$210.8M$142.8M$121.3M
Selling, general and administrative expenses$69.9M$62.5M$31.4M$28.2M$28.7M
Other expenses$0.00-$-2.24M-$-2.46M$0.00$0.00
Operating expenses$466.1M$341.6M$239.7M$171M$150M
Cost and expenses$468.2M$343.9M$242.2M$171M$150M
Interest income$29.9M$26.9M$7.64M$2.92M$740K
Interest expense$6.19M$0.00$0.00$2.92M$0.00
Depreciation and amortization$2.05M$2.24M$2.46M$1.68M$1.09M
Ebitda-$-437.97M-$-315.18M-$-233.48M-$-163.5M-$-148.2M
Operating income-$-468.18M-$-343.89M-$-242.16M-$-170.96M-$-150.03M
Total other income/expenses, net$22M$26.5M$6.22M$2.86M$730K
Income before tax-$-446.21M-$-317.42M-$-235.94M-$-168.1M-$-149.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-446.21M-$-317.42M-$-235.94M-$-168.1M-$-149.29M
Weighted average shares outstanding$128.4M$94.1M$59.7M$52M$50.9M
Weighted average diluted shares outstanding$128.4M$94.1M$59.7M$52M$50.9M
Balance sheet
20252024202320222021
Cash and short-term investments$1.11B$642.3M$123.1M$256M$376.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.13B$659.3M$129.4M$265.6M$382.4M
Property, plant and equipment, net$44.8M$30M$33.4M$38.4M$41M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$60.4M$32M$35.7M$40.7M$43.3M
Total assets$1.19B$691.2M$165.1M$306.3M$425.7M
Accounts payable$8.08M$6.56M$22.9M$5.26M$4.03M
Short-term debt$5M$4.85M$4.72M$4.61M$3.89M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$50.6M$42.3M$51.1M$28.1M$28.7M
Long-term debt$15.3M$19.1M$22.7M$25.9M$28.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$164.2M$19.1M$22.7M$25.9M$28.7M
Capital lease obligations$0.00$19.1M$27.4M$30.5M$32.6M
Total liabilities$214.8M$61.4M$73.8M$54M$57.5M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-1.4B-$-949.93M-$-632.51M-$-396.57M-$-228.47M
Accumulated other comprehensive income (loss)$470K$10K$0.00-$-570K-$-270K
Total equity$972.1M$629.8M$91.3M$252.4M$368.2M
Total investments$217.2M$206.8M$1.47M$83.9M$175.8M
Total debt$20.3M$24M$27.4M$30.5M$32.6M
Net debt-$-873.09M-$-411.46M-$-94.21M-$-141.66M-$-168.19M
Cash flow statement
20252024202320222021
Net income-$-446.21M-$-317.42M-$-235.94M-$-168.1M-$-149.29M
Depreciation and amortization$2.05M-$-1.93M$1.67M$1.68M$1.09M
Stock-based compensation$45.9M$45.9M$20M$15.2M$17.5M
Change in working capital-$-3.4M-$-19.49M$26.3M-$-5.38M$9.26M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$8.25M-$-8.96M$23M-$-1.24M$13.7M
Net cash provided by operating activities-$-403.21M-$-292.37M-$-188.16M-$-153.65M-$-119.56M
Investments in property, plant and equipment-$-1.92M-$-2.38M-$-730K-$-3.07M-$-3.62M
Acquisitions, net$0.00$0.00$0.00$30K$10K
Net cash used for investing activities-$-28.75M-$-204.08M$83.3M$87.2M-$-137.89M
Common stock issued$742.6M$773.1M$52.4M$36.9M$157.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$890.3M$809.9M$54.3M$37.4M$157.8M
Net change in cash$458.4M$313.5M-$-50.52M-$-29.05M-$-99.63M
Cash at end of period$895.7M$437.4M$123.9M$174.5M$203.5M
Operating cash flow-$-403.21M-$-292.37M-$-188.16M-$-153.65M-$-119.56M
Capital expenditure-$-1.92M-$-2.38M-$-730K-$-3.07M-$-3.62M
Free cash flow-$-405.13M-$-294.75M-$-188.89M-$-156.71M-$-123.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dyne Therapeutics, Inc.

        Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

        CEO
        John G. Cox
        Employees
        258
        Beta
        1.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Dyne Therapeutics, Inc. (DYN)?

        InvestorsCraft does not currently publish an intrinsic value for DYN. How the IC value is calculated.

        Is DYN undervalued?

        InvestorsCraft does not publish an undervaluation signal for DYN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.